JPMorgan Chase & Co. Has $28.65 Million Position in Twist Bioscience Corporation $TWST

JPMorgan Chase & Co. lessened its position in Twist Bioscience Corporation (NASDAQ:TWST) by 29.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,018,234 shares of the company’s stock after selling 420,892 shares during the period. JPMorgan Chase & Co.’s holdings in Twist Bioscience were worth $28,653,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of TWST. Campbell & CO Investment Adviser LLC lifted its holdings in Twist Bioscience by 227.6% during the third quarter. Campbell & CO Investment Adviser LLC now owns 47,200 shares of the company’s stock worth $1,328,000 after acquiring an additional 32,792 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in Twist Bioscience by 14.5% in the third quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company’s stock valued at $41,171,000 after acquiring an additional 184,726 shares during the period. Baillie Gifford & Co. increased its holdings in shares of Twist Bioscience by 62.8% in the third quarter. Baillie Gifford & Co. now owns 1,262,739 shares of the company’s stock worth $35,533,000 after acquiring an additional 487,052 shares in the last quarter. William Blair Investment Management LLC increased its holdings in shares of Twist Bioscience by 6.0% in the third quarter. William Blair Investment Management LLC now owns 4,142,283 shares of the company’s stock worth $116,564,000 after acquiring an additional 235,679 shares in the last quarter. Finally, New York State Common Retirement Fund raised its position in shares of Twist Bioscience by 14.0% during the third quarter. New York State Common Retirement Fund now owns 584,694 shares of the company’s stock worth $16,453,000 after purchasing an additional 71,777 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Barclays lifted their price objective on Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, February 3rd. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, February 3rd. Finally, Evercore upped their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.88.

Twist Bioscience Stock Up 5.8%

Twist Bioscience stock opened at $44.50 on Tuesday. The company has a current ratio of 3.78, a quick ratio of 3.37 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $57.88. The company has a fifty day simple moving average of $45.98 and a 200 day simple moving average of $36.05. The company has a market cap of $2.73 billion, a P/E ratio of -34.77 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The business had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The business’s revenue for the quarter was up 16.9% on a year-over-year basis. Research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In other news, CAO Robert F. Werner sold 7,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $45.65, for a total value of $319,550.00. Following the completion of the sale, the chief accounting officer owned 58,738 shares of the company’s stock, valued at approximately $2,681,389.70. This represents a 10.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Adam Laponis sold 7,000 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $50.00, for a total transaction of $350,000.00. Following the completion of the transaction, the chief financial officer directly owned 130,031 shares of the company’s stock, valued at $6,501,550. This represents a 5.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 48,190 shares of company stock valued at $2,234,695. 3.08% of the stock is owned by insiders.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.